2026 · 1st Quarter (Jan 1 - Mar 31)

BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Filed by BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.).

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 20, 2026
Income: Not reported
Expenses: $280,000.00
Registrant: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)
Client: BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)
Filing UUID: 12e1fca5-793d-4526-9450-80bea73b8142
Termination date: Not reported

Expense method: B

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

H.R.7148 - Consolidated Appropriations Act, 2026

Literal federal measure citations: H.R.7148

HCR · Health Issues

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Literal federal measure citations: S. 2211, H.R. 5461, S. 3064, S. 4189, H.R. 5467, S. 3105, H.R. 8018

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.